secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001104659-25-106631
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend
--------------------------------------------------------------------------------

- Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).
- Protein Sciences segment rev $202.2M (-1% YoY); op margin 38.4% vs 39.4%.
- Diagnostics & Spatial Biology rev $79.5M (-4%), organic +3%; op margin 11.2% vs 5.1% (benefited from Exosome divestiture).
- Completed Exosome Diagnostics divestiture; CEO notes biotech funding headwinds but stability in US academic.
- Declares quarterly dividend $0.08/share, payable Nov 28 to holders of record Nov 17.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000110465925106631/0001104659-25-106631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000110465925106631/tech-20251030x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-106631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer